On 28 April the HEcoPerMed Final Conference “Health Economics of Personalised medicine” took place. In the presence of Carman Laplaza Santos of the European Commission and Ejner Moltzen, President of ICPerMed, Prof. Maureen Rutten-van Mölken of Erasmus School of Health Policy & Management presented her article: 'Position Paper on Health Economics of Personalised Medicine'.
Also, Heleen Vellekoop, visiting lecturer at Erasmus School of Health Policy & Management and researcher at the institute for Medical Technology Assessment (iMTA) presented the results of the cost-effectiveness analysis of Entrectinib. This is one of the first tumor-agnostic treatments approved by EMA.
The position paper, as well as both presentations, can be looked back via: https://hecopermed.eu/final-conference/.